High-fat diet (HFD) causes renal lipotoxicity that is ameliorated with AMPK activation.
INTRODUCTION
The prevalence of obesity has continued to rise over the past few decades and was 36.5% among US adults between the years 2011 to 2014 (1) . Obesity serves as a significant risk factor both for the initiation and progression of kidney disease independent of hypertension and diabetes (2) (3) (4) . Excessive intake of calorie-dense lipids leads to organ dysfunction both by direct lipotoxicity and inflammation. In fact, the western diet enriched in saturated animal fats has been shown to increase albuminuria and cause a faster decline in renal function (5) . In our previous studies, we established that HFD induced kidney disease is characterized by renal hypertrophy, increased albuminuria and elevated markers of renal fibrosis and inflammation (6) . These HFD-induced markers of inflammation, oxidative stress, and fibrosis are reversed by AMP-activated protein kinase (AMPK) activation (6, 7) .
HFD alters the activity of crucial lipid metabolism enzymes Acetyl-CoA carboxylase (ACC) and HMG-CoA reductase (HMGCR) contributing to lipid accumulation in the kidney (6) . Total cholesterol esters and phosphatidylcholine content in the kidney are elevated while the fatty acid and triglyceride content is unchanged. Phospholipid accumulation in the proximal tubules is associated with lysosomal dysfunction, stagnant autophagic flux, mitochondrial dysfunction and inflammasome activation (8) . High-fat feeding for long periods causes recruitment of macrophages, switch to macrophage pro-inflammatory phenotype and increased inflammatory mediators like TNFα, MCP-1, IL-6, COX-2 and IL-1 (9-12). Diets rich in polyunsaturated fatty acids (PUFAs) are known to change plasma lipids, renal phospholipid content, and subsequently PUFA-derived eicosanoid inflammation in a rat model of nephrotic syndrome (13) . However, the influence of renal by guest, on March 15, 2019 www.jlr.org Downloaded from eicosanoid synthesis and eicosanoid derived inflammation in HFD induced kidney disease is unknown.
Eicosanoids are oxylipins derived from arachidonic acid (AA) or related PUFAs and are inextricably related to inflammation in the kidney. The primary PUFAs for the n-6 series and n-3 series, Linoleic acid (LA) and alpha-linolenic acid (ALA) respectively, are both derived from the diet. These 18-carbon PUFAs are then metabolized by various desaturase and elongase enzymes in a stepwise fashion. However, both LA or ALA are acted on by the same enzymes, resulting in a competition between the n-3 and n-6 series (14) . LA is metabolized through multiple steps to dihomo--linolenic acid (DGLA, 20:3n6) and, ultimately, to AA (20:4n6) . On the other hand, ALA is metabolized to eicosapentaenoic acid (EPA, 20:5 n-3) and subsequently to docosahexaenoic acid (DHA, 22:6 n-3) (15) . These PUFAs are incorporated into membrane phospholipids and released by phospholipase A2 (PLA2) under the influence of various stimuli. In subsequent reactions, cyclooxygenases (COX), lipoxygenases (LOX), cytochrome P450 (P450) enzymes act on free PUFAs to form eicosanoids. Some eicosanoids can also be formed from PUFAs via non-enzymatic reactions (NE), e.g., isoprostanes.
Eicosanoids play an essential role in the regulation of renal physiology and disease by modulating renal blood flow, glomerular filtration rate, autoregulation, tubular glomerular feedback, excretion of renal water and sodium, and release of renin and erythropoietin. HFD feeding causes an increase in circulating eicosanoids. In the kidney, these eicosanoids are produced by all different cell types -mesangial cells, renal microvessels, and tubular cells. This makes it difficult to pinpoint the actual origin of these autacoids without actual profiling of the various compartments. Local production in the by guest, on March 15, 2019 www.jlr.org Downloaded from kidney will be reflected in the kidney tissue, renal venous compartment, and urine. Recent advances in eicosanoid analysis using highly sensitive mass spectrometry (MS) has enabled us to profile over 150 different eicosanoid metabolites reliably in all tissues, enabling us to systematically profile the changes in the metabolic pathways with HFD and AICAR therapy.
AMPK is a ubiquitous, heterotrimeric kinase that acts as a cellular energy sensor that responds to changes in the intracellular AMP/ATP ratio (16) . AICAR (5-aminoimidazole-4-carboxamide-1--D-furanosyl 5'-monophosphate) acts as a specific AMPK agonist (17) . AMPK activation leads to inhibition of energy-requiring biochemical processes like fatty acid synthesis and stimulation of energy-producing biochemical pathways like betaoxidation to improve energy efficiency (18) . Metabolic stress such as diabetes or obesity impair the activity of AMPK, and AMPK activation reduces the initial and sustained inflammatory response in the kidney of the HFD-induced kidney disease model (6) . Along with lipid accumulation, the markers of inflammation were modulated with AICAR use (7).
AMPK signaling has been shown to influence the secretory PLA2 expression in vascular smooth muscle cells (19) and control triglyceride content in adipocytes (20) . AMPK activation also decreases the formation of 15-LOX metabolites of AA in macrophages (21) . While AMPK activation is beneficial in lipid and eicosanoid metabolism in other tissues, the effect of HFD and AMPK activation on eicosanoid pathways in the kidney is unknown. We hypothesized that the high-fat exposure triggers inflammation involving the eicosanoid pathway and that eicosanoid production is ameliorated with AMPK activation.
We used a targeted lipidomic platform to systematically investigate the HFD-associated eicosanoid synthesis induced in mice consuming HFD with or without AMPK activation in by guest, on March 15, 2019 www.jlr.org Downloaded from order to better understand the pathophysiological processes involved in the HFD-induced kidney disease.
RESULTS

HFD increased phospholipase expression and free levels of polyunsaturated fatty acids and this action is reversed by AMPK activation.
Both cytosolic and secretory PLA2 act on membrane phospholipids to release PUFA's-the precursor of various eicosanoids. Levels of cytosolic phospho-PLA2 (Group IV) and secretory PLA2 were both increased with HFD in the kidney, and AICAR treatment decreased their levels (Figure 1 ).
Targeted lipidomic analysis using MS of kidney tissue revealed unique patterns in the total, and free ω3 and ω6 PUFA series that are demonstrated in Figure 2 . The total fatty acid (FA) (esterified and unesterified FA) and free FA (unesterified, FFA) profiles generated from the kidney of mice fed a low fat, standard chow (STD), HFD or HFD with the AMPK activator AICAR (HFD+AICAR) are displayed in Supplemental Table 1 . The total and free EPA are decreased in the kidneys with the HFD (Figure 2A and B, p<0.05) and further decreased with AICAR, while both total and free DHA, a n3 fatty acid similar to EPA, is increased with HFD and reversed with the use of AICAR (Figure 2C and D, p<0.05). While DHA and EPA levels are modulated with HFD, the parent PUFA-ALA (total and unesterified) is unchanged.
Free and total n6 fatty acid DGLA is decreased in the kidney with HFD but unchanged with AICAR ( Figure 2E and F) . Total and free AA in the kidney are increased by guest, on March 15, 2019 www.jlr.org
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by HFD and the free AA decreased with AICAR ( Figure 2G and H) . Free and total levels of LA, the precursor for both DGLA and AA are unchanged by the diet and AICAR in the kidney. Delta-6 desaturase (D6D) and delta-5 desaturase (D5D) catalyze desaturations at specific positions of FA substrates. Elongases extend the fatty acid carbon chains by two carbons. The levels of both desaturases were not different between the three groups (Supplementary Figure 1) .
HFD dysregulates kidney eicosanoid metabolism that is ameliorated by AMPK activation.
The eicosanoid metabolites of AA, DHA and EPA are regulated with HFD in the kidney (Table 1) , and specific metabolites are modulated with AICAR (Figure 3) . HFD seems to create a clear increase in COX products of AA in the kidney and decrease in COX products of EPA. 12-hydroxyl-hexadecatrienoic acid (12HHT) which is a COX / P450 product is increased with HFD and decreased with AICAR ( Figure 3A) . P450 products of DHA -16, 17-epoxy-docosapentaenoic acid (16, and its product 16-hydroxydocosahexaenoic acid , and 19,20-epoxy-docosapentaenoic acid (19, and its product 19,20-dihydroxy-docosapentaenoic acid (19, are increased with HFD, but only the end products 19,20-DiHDPA and 16-HDoHE are decreased with AICAR ( Figure 3B and C) . LOX products of DHA-hydroxydocosahexaenoic acids (HDoHE): 4-HDoHE, 7-HDoHE, 11-HDoHE, and 17-HDoHE and its product -15 (t)-protectin D1 (15 (t)-PD1) are increased with HFD ( Figure 3D , 3E, and 3F). NE degradation products of DHA-8-HDoHE, 10-HDoHE, 13-HDoHE, and 20-HDoHE are increased with HFD and decreased with AICAR ( Figure 3G and 3H) . HFD induced changes in urine metabolites are illustrated in Table 2 and the metabolites that are altered with AICAR in Figure 4 . The overall trend of the kidney continues in the urine with predominant increase of COX products of AA in the urine and decrease of COX products of EPA. Adrenic acid and its COX metabolite dihomo-prostaglandin PGF2α (dihomo-PGF2α) are both increased with HFD in the urine but only dihomo-PGF2α is decreased with AICAR ( Figure 4A ). Dihomo-15-deoxyprostaglandin D2 (dihomo-15d-PGD2) which is a NE byproduct of another Adrenic acid COX metabolite is decreased with HFD and increased with AICAR ( Figure 4B ).
Urine AA (Figure 4C ) is increased with HFD and decreased with AICAR which is consistent with the trend in the kidney. Downstream COX metabolites of AA and prostaglandin H2 (PGH2) are altered with the HFD and AICAR. P450 metabolite of prostaglandin E2 (PGE2) metabolites -13,14-dihydro-15-keto-prostaglandin E2 (PGEM, Figure 4D ) is increased with HFD and decreased with AICAR. Another PGH2 metabolite-13,14-dihydro-5-keto-prostaglandin F2α (PGFM, Figure 4E ) and prostaglandin F2α (PGF2α, Figure 4F ) both the products of COX are increased with HFD and decreased with HFD with AICAR. Prostaglandin D2 (PGD2) metabolite -prostaglandin J2 (PGJ2) is increased with HFD, while urinary 13,14-dihydro-15-keto-prostaglandin D2 (dhk-PGD2; 
HFD and AMPK activation modulate circulating eicosanoid levels
In order to delineate the origin of the eicosanoids in the kidney, both the renal artery ( Table 3 ) and vein ( Table 4 LA metabolites of P450 -9,10-dihydroxy-octadecaenoic acid (9,10-diHOME), 12,13-dihydroxy-octadecaenoic acid (12,13-diHOME), and 12,13-epoxy-octadecaenoic acid (12,13-EpOME) are decreased with HFD and are increased with AICAR in the arterial circulation (Figure 5A-C) . Venous sampling revealed that 9-hydroxy-octatrienoic acid (9-HOTrE) is a product of LOX derived from ALA is decreased with HFD but increased with AICAR ( Figure 5D ). 5-HEPE is LOX metabolites of EPA is decreased with HFD and increased with AICAR treatment (Figure 5E ).
Specific eicosanoids are altered by AMPK activation
When taken as a whole, there were significant changes in eicosanoid pathways in arterial and venous circulation, urine and kidney compartments (Supplementary Table 2 ). Figure 6 depicts the changes influenced by AICAR therapy on HFD mice. To further detect trends in the changes, the highly correlated eicosanoids derived from a parent PUFA and acted on by a specific enzymatic pathways were collapsed in to principal components and analyzed for trends and statistical significance. 
DISCUSSION
This is the first study to systematically explore the effects of HFD on eicosanoid synthesis in the kidney and the role of AMPK activation in ameliorating these changes. We find that HFD increases phospholipase A2 expression and activity (through phosphorylation) in the kidney that is largely corrected by AMPK activation. HFD increases both the proinflammatory AA and the anti-inflammatory DHA, and their respective downstream products in the kidney and urine and these changes are reversed with AICAR therapy.
However, HFD decreases EPA, DGLA, and LOX and NE metabolites of EPA, while AICAR therapy decreases free EPA levels further in the kidney. P450 and NE of LA were decreased in the arterial circulation with HFD are returned to pre-HFD levels with AICAR.
These changes highlight the changes in eicosanoid pathways in the kidney with HFD that are ameliorated by AICAR therapy.
Obesity and metabolic syndrome patients have demonstrated altered fatty acid and eicosanoid metabolism compared to lean subjects. Increased serum DGLA levels and low delta-5 desaturase activity was associated with hepatic steatosis over and above conventional risk factors in metabolic syndrome subjects (22) . Like our HFD mouse model, COX, LOX, and P450 metabolites of AA and other PUFA's are elevated in the plasma of obese subjects compared to lean subjects (23) . Increased TXA2 can cause vasoconstriction and induce transcription of collagen in the glomerular matrix. In contrast, PGI2 counteracts the deleterious TXA2 effects associated with progressive glomerular damage by acting as a vasodilator. Decreased urinary PGI2/TXA2 ratio has been demonstrated in diabetic humans compared to controls (24) . In the Japanese population, urinary 8-iso-PGF2α which is a AA metabolite predicts metabolic risks like obesity, hypertension, and glucose tolerance (25) . Meanwhile, low serum lipoxin A4 levels (AA metabolite) are associated with metabolic syndrome risk in Chinese population, similar to the elevated kidney levels of lipoxin A4 and its metabolite in our study (26) .
Obesity-induced kidney disease is characterized by glomerular enlargement, podocytes loss, and proteinuria eventually leading renal failure (2, 27, 28) . In animal models, HFD increased kidney weight and glomerular area with Periodic -Acid-Schiff decreased PGE2 excretion rates were evident in obese Zucker rats. Similarly, decreased urinary PGI2/TXA2 ratio has been demonstrated in diabetic humans as well as in diabetic animal models. Rofecoxib, a COX-2 inhibitor, decreases vascular and glomerular damage when administered to obese Zucker rats (24) . Decreased PGF2α and 8-iso-PGF2α levels contribute to the decreased glomerulosclerosis in obese Zucker rats treated with rofecoxib. COX-2 inhibition and decreases in 8-iso-PGF2α levels have also been shown to ameliorate renal injury associated with hypertensive rats (45). This pattern is also reflected in the urinary levels of 8-iso-PGF2α in our mouse model of HFD induced kidney disease.
Renal P450 epoxidation generates epoxyeicosatrienoic acids (EETs) that are metabolized by soluble epoxide hydrolase (sEH) to less active dihydroxyeicosatrienoic acids (DHETEs). Decreased renal expression of CYP2C epoxygenase enzymes has been observed in diabetes, high fat diet fed insulin resistance rats, and the kidney and mesenteric blood vessels of obese Zucker rats (46). Additionally, sEH expression is increased in blood vessels of obese rats and could further contribute to the decrease in EET bioavailability implicating impaired endothelial dilator responses in obesity and diabetes. Cytokines-IL-6 and TNF-α decrease expression of P450 epoxygenase enzymes. TNF-α and EET's act via NFκB pathway causing elevated MCP-1 levels that have been observed in HFD induced kidney disease in mice (6) . Obese Zucker rats have increased renal vascular CYP4A expression and increased generation of 20-HETE (47).
However, renal tubular CYP4A expression was decreased in Sprague-Dawley rats on HFD (48) . AA metabolites -20-HETE, EET, and DHETE are decreased with HFD in the by guest, on March 15, 2019 www.jlr.org Downloaded from kidney and associated with the diet-induced change in blood pressure and renal function of Sprague-Dawley rats (48, 49) . In our study, the kidney P450 products of AA-9-HETE and EET's are increased with HFD just as many of the EET's are also increased in the circulation and urine. Pharmacological inhibition or transgenic deletion of sEH, the dominant enzyme in degrading EETs, have been shown to protect mice from various adverse effects induced by obesity (50) . Thus, protective eicosanoid metabolites of AA-EET are increased with HFD in the kidney. In HFD fed mice, plasma profiling revealed increases in circulating P450 metabolite of LA-EpOME's (51) which is a different trend to the one observed in the arterial circulation of our HFD mice maintained on HFD for a longer period.
Central adipose tissue in obese Zucker rats shows increased LOX expression along with inflammatory markers (52). 5-LOX products induce NF-kappaB expression and secretion of inflammatory cytokines like MCP-1, TNF-α, macrophage inflammatory protein-1gamma, and IL-6 by the adipose tissue. The 5-LOX pathway plays a major role in obesity-induced fatty liver disease (53) . In our study, LOX metabolites of AA, AA metabolites-6(R),15 (R)-LXA4 and 6(S)-LXA4 are increased in the kidney with HFD in our study, and LXA4 has been shown by our group to attenuate inflammation in HFD related kidney disease (10) . Similarly, LOX metabolites of DHA -HDoHE were elevated in the kidney, whereas LOX metabolites of EPA -HEPE's were all decreased in the kidney and the circulation. HFD has been previously shown to increase leukotoxins-EpOME, while in our study, EpOME metabolites are decreased (51). AICAR also reverses the downregulation of 9,10 DiHOME, 12, 13-DiHOME, and 12,13-EpOME in the arterial circulation in our study. Thus, AMPK activation is able to reverse key pathways in eicosanoid metabolism and helps ameliorate changes resulting from HFD.
In this current study, we demonstrate modulation of PUFA's and their metabolites after HFD as well as AMPK activation in the kidney, but we cannot delineate the origin of the various eicosanoids in the circulation and urine which could be from the diet, liver, muscle, pancreas and/or gut microbiota. Again, the changes in the eicosanoids might be influenced by the upstream action of phospholipases on specific PUFA's whose pattern might be reflective of the specific diet; Although both the diets had a similar n6: n3 ratio, the specific composition of HFD might have influenced the eicosanoid changes. Also, as the influence of AICAR is not restricted to one specific oxygenase or PUFA, its influence 
PBS via intraperitoneal injections for five days a week for a total of 14 weeks (6). Mice
were placed in metabolic cages for 24-h urine collection before the start of the diets and after 14 weeks. Mice were sacrificed after 14 weeks of diet plasma was collected from the renal vein, and arterial blood was obtained from direct cardiac puncture. After perfusion with PBS, kidneys were snap-frozen in liquid nitrogen for further analysis.
Quantitative total and free fatty acids analysis:
Total and free fatty acids were analyzed by gas chromatography/mass spectrometry (GC-MS) as previously described (62, 63) . Free fatty acids were extracted from 50 μL of the kidney tissue homogenates that was supplemented with a set of deuterated fatty acids that served as internal standards. The extraction was initiated by the addition of 25 μL 1N hydrochloric acid, and 500 μL methanol and a bi-phasic solution were formed by the addition of 1 mL isooctane. The isooctane phase containing the free fatty acid fraction is removed, the extraction is repeated once more, and the combined extracts are dried under argon before analysis with the GC/MS.
In preparation for GC-MS analysis, the fatty acids-both total fatty acid after saponification and free fatty acid extracted from samples and the quantitative standards acid metabolite-9,10-dihydroxy-octadecaenoic acid (9,10-diHOME); 12,13, Epoxyoctadecaenoic acid (12,13-EpOME) and, 12,13,dihydroxyoctadecenoic acid (12,13-diHOME). P450-cytochrome P450; LOX -lipoxygenases; COX -cyclooxygenase; NE -non-enzymatic. Red font indicates that high-fat diet increases these metabolites and AICAR reverses this, while blue font indicates the metabolite is decreased with highfat diet and AICAR reverses this trend.
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